english Archives - 29 중 2 번째 페이지

Samsung Biologics Secures Land Equivalent to 26 Soccer Fields in Songdo…To Produce ADCs and Other Advanced Therapies

Bird’s-eye rendering of Samsung Biologics’ Third Bio Campus. Photo=Samsung Biologics. Samsung Biologics is significantly expanding its handling of next-generation therapeutics as it strengthens the growth engine of its contract development…

Park Pyeongtak

2025-12-01

Celltrion: “Zympentra Shows Consistent Therapeutic Effect Across All Intestinal Inflammatory Sites”

Zympentra. photo=Celltrion Celltrion announced that its autoimmune disease therapy Zympentra—the U.S. brand name for the subcutaneous (SC) formulation of Remsima (active ingredient: infliximab)—demonstrated significant therapeutic effects regardless of the location…

Park Pyeongtak

2025-11-26

HK inno.N to Surpass 1Trillion won in Sales Despite Slump in “Condition” Brand

Despite the ongoing slump of its flagship hangover-relief drink “Condition,” HK inno.N is expected to surpass ₩1 trillion in annual revenue this year. Although the company has been hit by…

Park Pyeongtak

2025-11-25

Celltrion Bets on Oral Obesity Drug: “The Wegovy Era Won’t Last Long”

Celltrion is set to enter the growing market for oral obesity drugs, aiming to overcome the limitations of existing therapies—such as adverse effects and muscle loss—by enhancing efficacy and minimizing…

Park Pyeongtak

2025-11-19

Bukwang Pharm: “Spinning Off Danish Subsidiary and Strengthening Momentum for RNA Therapeutics Development”

Bukwang Pharm announced on the 18th that its Danish subsidiary Contera Pharma will spin off its RNA therapeutics division to establish a new company. The decision reflects Chairwoman Ahn Mi-jeong’s…

Park Pyeongtak

2025-11-18

ABL Bio Sets Sights on Obesity Drug Market

ABL Bio, which recently secured a major technology licensing deal and equity investment from global pharma giant Eli Lilly, announced that its next strategic move will be entering the fast-growing…

Park Pyeongtak

2025-11-17

The Obesity Drug Boom: How Long Can the Rally Last?

A stock price soaring 6.1 times in just 10 months — from 49,100 won to 299,000 won — and a market capitalization jumping from 533 billion won (about USD 390…

Park Pyeongtak

2025-11-06

SK Biopharm’s Epilepsy Drug ‘Xcopri’ Wins Korean Approval

SK Biopharm’s Epilepsy Drug ‘Xcopri,’ with ₩400 Billion ($290 Million) Annual U.S. Sales, Wins Korean Approval SK Biopharm’s epilepsy medication Xcopri (generic name: cenobamate), which generates over ₩400 billion (approximately…

Cheon Okhyeon

2025-11-03

India’s Molbio Diagnostics Wins 18th Kochon Prize for TB Innovation

A round of applause filled a hall in Manila, the Philippines, on the evening of October 29, as an Indian company dedicated to fighting tuberculosis was named the winner of…

Cheon Okhyeon

2025-10-30

HK inno.N Nears KRW1 Trillion in Annual Sales

HK inno.N has recorded cumulative sales of around KRW770 billion($554 million) as of the third quarter this year, bringing the company closer than ever to achieving KRW1 trillion($720 million) in…

Park Pyeongtak

2025-10-29